Inclusion body myositis.

Sporadic inclusion body myositis is a severely disabling muscle disease that mainly affects elderly individuals. The typical distribution of muscle weakness, poor response to immunosuppressive treatment, pathological accumulation of various proteins in vacuolated muscle fibres, inflammatory reaction and mitochondrial changes have all been subjects of recent research that has led to better understanding of the pathogenic events that leads to muscle degeneration and weakness.

[1]  K. Felice,et al.  Further observations on forearm flexor weakness in inclusion body myositis , 1998, Muscle & nerve.

[2]  I. Lundberg,et al.  New developments in the role of cytokines and chemokines in inflammatory myopathies. , 1998, Current opinion in rheumatology.

[3]  R. Hennekam,et al.  Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy. , 1998, Arthritis and rheumatism.

[4]  W. Engel,et al.  Sporadic inclusion-body myositis and its similarities to Alzheimer disease brain. Recent approaches to diagnosis and pathogenesis, and relation to aging. , 1998, Scandinavian journal of rheumatology.

[5]  George M. Martin,et al.  Transgenic Mice Over-Expressing the C-99 Fragment of βPP with an α-Secretase Site Mutation Develop a Myopathy Similar to Human Inclusion Body Myositis , 1998 .

[6]  W J Litchy,et al.  Inclusion body myositis. Observations in 40 patients. , 1989, Brain : a journal of neurology.

[7]  W. Engel,et al.  Increase of nitric oxide synthases and nitrotyrosine in inclusion‐body myositis , 1996, Neuroreport.

[8]  F. Mastaglia,et al.  Treatment of inflammatory myopathies , 1997, Muscle & nerve.

[9]  Hagen H. Kitzler,et al.  Methionine homozygosity at prion gene codon 129 may predispose to sporadic inclusion-body myositis , 1999, The Lancet.

[10]  A. Tarkowski,et al.  Restricted use of T cell receptor V genes in endomysial infiltrates of patients with inflammatory myopathies , 1994, European journal of immunology.

[11]  A Seller,et al.  Normal in vivo skeletal muscle oxidative metabolism in sporadic inclusion body myositis assessed by 31P-magnetic resonance spectroscopy. , 1998, Brain : a journal of neurology.

[12]  A. Roses,et al.  Apolipoprotein E alleles in sporadic inclusion‐body myositis and hereditary inclusion‐body myopathy , 1996, Annals of neurology.

[13]  R Hohlfeld,et al.  Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. , 1996, The Journal of clinical investigation.

[14]  R. Hohlfeld,et al.  Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions. , 1998, Journal of immunology.

[15]  W. Engel,et al.  Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: current concepts of diagnosis and pathogenesis. , 1998, Current opinion in rheumatology.

[16]  D. Arnold,et al.  Intracellular phosphates in inclusion body myositis—A 31P magnetic resonance spectroscopy study , 1998 .

[17]  S. Ledoux,et al.  The Amyloid β Protein Induces Oxidative Damage of Mitochondrial DNA , 1997 .

[18]  M. Dalakas,et al.  An inflammatory, familial, inclusion body myositis with autoimmune features and a phenotype identical to sporadic inclusion body myositis. Studies in three families. , 1997, Brain : a journal of neurology.

[19]  E. Shoubridge,et al.  Characterization of the mitochondrial DNA abnormalities in the skeletal muscle of patients with inclusion body myositis. , 1998, Journal of neuropathology and experimental neurology.

[20]  H. W. Harris,et al.  Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[21]  A. Oldfors,et al.  Analysis of multiple mitochondrial DNA deletions in inclusion body myositis , 1997, Human mutation.

[22]  Yasuo Ihara,et al.  Chloroquine myopathy suggests that tau is degraded in lysosomes: implication for the formation of paired helical filaments in Alzheimer's disease , 1998, Neuroscience Research.

[23]  A. Engel,et al.  Immunocytochemical study of CD45 T cell isoforms in inflammatory myopathies. , 1995, The American journal of pathology.

[24]  D. Hutchinson.  Inclusion body myositis , 1998, Neurology.

[25]  W. Engel,et al.  Immunolocalization of transcription factor NF-κB in inclusion-body myositis muscle and at normal human neuromuscular junctions , 1998, Neuroscience Letters.

[26]  F. Mastaglia,et al.  Immunoglobulin therapy in inflammatory myopathies , 1998, Journal of neurology, neurosurgery, and psychiatry.

[27]  A. Oldfors,et al.  Upregulation of Fas/Fas ligand in inclusion body myositis , 1998, Annals of neurology.

[28]  M. Dalakas,et al.  HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies , 1998, Journal of Neuroimmunology.

[29]  Kucharz Ej.  [Inclusion body myositis]. , 1998, Polskie Archiwum Medycyny Wewnetrznej.

[30]  S. Welle,et al.  Ragged Red Fibers in Normal Aging and Inflammatory Myopathy , 1995, Annals of neurology.

[31]  S. Love,et al.  Apolipoprotein E allele frequencies in sporadic inclusion body myositis , 1996, Muscle & nerve.

[32]  W. Engel,et al.  Fourteen Newly Recognized Proteins at the Human Neuromuscular Junctions‐and Their Nonjunctional Accumulation in Inclusion‐Body Myositisa a , 1998, Annals of the New York Academy of Sciences.

[33]  W. Engel,et al.  Light and electron microscopic immunolocalization of presenilin 1 in abnormal muscle fibers of patients with sporadic inclusion-body myositis and autosomal-recessive inclusion-body myopathy. , 1998, The American journal of pathology.

[34]  N. Darín,et al.  Dominant hereditary inclusion-body myopathy gene (IBM3) maps to chromosome region 17p13.1. , 1999, American journal of human genetics.

[35]  H. Goebel,et al.  Cell death and oxidative damage in inflammatory myopathies. , 1998, Clinical immunology and immunopathology.

[36]  J. Tschopp,et al.  Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways , 1994, Nature.

[37]  D. Selkoe,et al.  Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau. , 1994, The American journal of pathology.

[38]  J. Schröder,et al.  Pleomorphic mitochondrial and different filamentous inclusions in inflammatory myopathies associated with mtDNA deletions , 1998, Acta Neuropathologica.

[39]  M. Dalakas,et al.  Safety and efficacy of strength training in patients with sporadic inclusion body myositis , 1997, Muscle & nerve.

[40]  Marinos C. Dalakas,et al.  Rimmed vacuoles with β-amyloid and ubiquitinated filamentous deposits in the muscles of patients with long-standing denervation (postpoliomyelitis muscular atrophy): similarities with inclusion body myositis , 1998 .

[41]  C. L. Jackson,et al.  Fine-structure mapping of the hereditary inclusion body myopathy locus. , 1999, Genomics.

[42]  E. Holme,et al.  Clonal expansion of mitochondrial DNA with multiple deletions in autosomal dominant progressive external ophthalmoplegia , 1996, Annals of neurology.

[43]  A. Engel,et al.  Sporadic inclusion body myositis: Counts of different types of abnormal fibers , 1996, Annals of neurology.

[44]  I. Nonaka,et al.  Immunohistochemical analysis of perforin and granzyme A in inflammatory myopathies , 1994, Neuromuscular Disorders.

[45]  R. Hohlfeld,et al.  Cytotoxic mechanisms in inflammatory myopathies. Co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells. , 1997, Brain : a journal of neurology.

[46]  J. Trapani,et al.  Granzymes: exogenous proteinases that induce target cell apoptosis. , 1995, Immunology today.

[47]  J. Dambrosia,et al.  Treatment of inclusion-body myositis with IVIg , 1997, Neurology.

[48]  S. Dimauro,et al.  Inclusion body myositis and myopathies , 1995, Annals of neurology.

[49]  A. Oldfors,et al.  Limited T‐Cell Receptor V Gene Usage in Inclusion Body Myositis , 1996, Scandinavian journal of immunology.

[50]  M. Dalakas,et al.  The αβ T-Cell Receptor Repertoire in Inclusion Body Myositis: Diverse Patterns of Gene Expression by Muscle-infiltrating Lymphocytes , 1994 .

[51]  M. Dalakas,et al.  Immune‐mediated conditions and antibodies associated with sporadic inclusion body myositis , 1998, Muscle & nerve.

[52]  F L Mastaglia,et al.  Apolipoprotein E ϵ4 in inclusion body myositis , 1995 .

[53]  Charles R. Harringtonaa,et al.  Apolipoprotein E type ϵ4 allele frequency is not increased in patients with sporadic inclusion-body myositis , 1995, Neuroscience Letters.

[54]  A. Oldfors,et al.  Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases , 1994, Acta Neurologica Scandinavica.

[55]  N. Darín,et al.  Autosomal dominant myopathy with congenital joint contractures, ophthalmoplegia, and rimmed vacuoles , 1998, Annals of neurology.

[56]  I. Hausmanowa-Petrusewicz,et al.  Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. , 1997 .

[57]  P. Barkhaus,et al.  Quantitative electrophysiologic studies in sporadic inclusion body myositis , 1999, Muscle & nerve.

[58]  M. Dalakas,et al.  Treatment of inclusion‐body myositis with high‐dose intravenous immunoglobulin , 1993, Neurology.

[59]  U. Andersson,et al.  Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. , 1997, Arthritis and rheumatism.

[60]  A. Engel,et al.  Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis , 1984, Annals of neurology.

[61]  R Luft,et al.  The development of mitochondrial medicine. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Reinhard Hohlfeld,et al.  T-cell heterogeneity in muscle lesions of inclusion body myositis , 1998, Journal of Neuroimmunology.

[63]  M. Dalakas,et al.  Magnetic resonance imaging of the forearm as a diagnostic aid in patients with sporadic inclusion body myositis , 1997, Neurology.

[64]  E. Holme,et al.  Mitochondrial DNA Deletions in Muscle Fibers in Inclusion Body Myositis , 1995, Journal of neuropathology and experimental neurology.

[65]  I. Nishino,et al.  Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. , 1999, Science.

[66]  M. Dalakas,et al.  Controlled Studies with High-Dose Intravenous Immunoglobulin in the Treatment of Dermatomyositis, Inclusion Body Myositis, and Polymyositis , 1998, Neurology.

[67]  W. Engel,et al.  New advances in inclusion-body myositis. , 1993, Current opinion in rheumatology.

[68]  Christopher Lindberg,et al.  Oligoclonal expansion of muscle infiltrating T cells in inclusion body myositis , 1997, Journal of Neuroimmunology.

[69]  Christopher Lindberg,et al.  T cell receptor β-chain repertoire in inclusion body myositis , 1998, Journal of Neuroimmunology.

[70]  M. Strome,et al.  Dysphagia in patients with inclusion body myositis , 1998, The Laryngoscope.

[71]  W. Trojaborg,et al.  The role of quantitative electromyography in inclusion body myositis , 1997, Journal of neurology, neurosurgery, and psychiatry.

[72]  R. Mantegazza,et al.  The expression of co-stimulatory and accessory molecules on cultured human muscle cells is not dependent on stimulus by pro-inflammatory cytokines: relevance for the pathogenesis of inflammatory myopathy , 1998, Journal of Neuroimmunology.

[73]  W. Engel,et al.  β‐Amyloid precursor epitopes in muscle fibers of inclusion body myositis , 1993 .

[74]  L. Peltonen,et al.  Assignment of the tibial muscular dystrophy locus to chromosome 2q31. , 1998, American journal of human genetics.

[75]  Margaret A. Johnson,et al.  Role of mitochondrial DNA mutations in human aging: Implications for the central nervous system and muscle , 1998, Annals of neurology.

[76]  J R Lindsey,et al.  Amyloid-beta deposition in skeletal muscle of transgenic mice: possible model of inclusion body myopathy. , 1998, The American journal of pathology.

[77]  F L Mastaglia,et al.  HLA associations with inclusion body myositis , 1994, Clinical and experimental immunology.

[78]  H. Hartung,et al.  MHC Class l‐Mediated Cytotoxicity Does Not Induce Apoptosis in Muscle Fibers nor in Inflammatory T Cells: Studies in Patients with Polymyositis, Dermatomyositis, and Inclusion Body Myositis , 1996, Journal of neuropathology and experimental neurology.

[79]  S. Tsuji,et al.  Gene locus for autosomal recessive distal myopathy with rimmed vacuoles maps to chromosome 9 , 1997, Annals of neurology.

[80]  A. Amato,et al.  Inclusion body myositis in twins , 1998, Neurology.

[81]  R. Dengler,et al.  Inclusion body myositis: immune globulins improve muscle strength, but not abnormal postures , 1998, Journal of Neurology.

[82]  W. Engel,et al.  βAPP gene transfer into cultured human muscle induces inclusion‐body myositis aspects , 1997 .

[83]  MD G. J. D. Hengstman,et al.  Presence of the anti–Jo‐1 autoantibody excludes inclusion body myositis , 1998, Annals of neurology.